<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03958786</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS EP66 SEPTAVIH</org_study_id>
    <nct_id>NCT03958786</nct_id>
  </id_info>
  <brief_title>Frailty in People Living With HIV Aged 70 Years or More</brief_title>
  <official_title>Frailty in People Living With HIV Aged 70 Years or More : Screening Feasibility, Prevalence, Risk Factors and Impact on Pejorative Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ANRS EP66 SEPTAVIH Study aims to screen feasibility of evaluating frailty in people&#xD;
      living with HIV aged 70 or older, to estimate its prevalence, to analyse associated risk&#xD;
      factors and to evaluate the impact of frailty on pejorative events.&#xD;
&#xD;
      SEPTAVIH is a French, multicentre, prospective, observational study which will include 500&#xD;
      HIV-infected participants&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to assess the prevalence of frailty at baseline in People living&#xD;
      with HIV (PLWH) aged 70 years and older, using the Fried index.&#xD;
&#xD;
      The main secondary objectives of this study are :&#xD;
&#xD;
        -  To assess frequency frailty according to different indexes or scores (Fried, Health&#xD;
           deficits Index, HAS score, VACS index)&#xD;
&#xD;
        -  To evaluate the association between frailty and specific HIV-related characteristics&#xD;
           (for example known duration of HIV infection), or non-specific factors (such as non-&#xD;
           HIV-related diseases or living conditions)&#xD;
&#xD;
        -  Proportion of subjects with a pejorative event at 12 months of follow-up (recurrent or&#xD;
           serious falls, emergency department visit, unscheduled hospitalization,&#xD;
           institutionalization, loss of one point on the IADL scale or death)&#xD;
&#xD;
        -  Association between baseline evaluation of frailty and pejorative events incidence&#xD;
           during the 12 months of follow-up.&#xD;
&#xD;
        -  Transition between frail or non frail status during the 12 months of follow-up&#xD;
&#xD;
        -  To assess the prevalence of sarcopenia and osteoporosis&#xD;
&#xD;
        -  To describe study population including :&#xD;
&#xD;
             -  Demographic characteristics&#xD;
&#xD;
             -  HIV medical history and antiretroviral therapy&#xD;
&#xD;
             -  Comorbidities, polymedication and evaluation of drug-drug interactions&#xD;
&#xD;
             -  Mental Health, quality of life, socioeconomic status&#xD;
&#xD;
             -  Healthcare use and additional care implementation (nursing, physical therapy, home&#xD;
                care services, …)&#xD;
&#xD;
        -  Assessment of Inflammatory and Immunosenescence biomarkers at Baseline&#xD;
&#xD;
        -  Anthropologic substudy about hiv and polypathologies management&#xD;
&#xD;
        -  Focus COVID-19 with clinical questionnaire, self-administrated questionnaire, SARS CoV2&#xD;
           serology and biobank (serum library)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 15, 2019</start_date>
  <completion_date type="Anticipated">June 22, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of frail patients</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of patients classified as frail according to Fried at Baseline</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">512</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>500 HIV-1 infected patients, aged 70 years and older</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Simplified Geriatric Evaluation</intervention_name>
    <description>Questionnaires&#xD;
Self assessment questionnaires&#xD;
Mobility and balance tests</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sampling</intervention_name>
    <description>- Blood samples : 35 ml will be collected at baseline, after signature of written informed consent, 7 ml at M12</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged 70 years and older&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  Antiretroviral therapy for at least 12 months&#xD;
&#xD;
          -  Free and signed informed consent (article L1122-1-1-1 of the French Public Health&#xD;
             Code)&#xD;
&#xD;
          -  Person affiliated or benefiting from a social security scheme -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in another research study excluding participation in other studies&#xD;
&#xD;
          -  Person under legal protection or deprived of liberty by a judicial or administrative&#xD;
             decision&#xD;
&#xD;
          -  Isolated HIV-2 infection&#xD;
&#xD;
          -  Life expectancy of less than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clotilde ALLAVENA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases - CHU Nantes- France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence MEYER</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM CESP - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hubert BLAIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geriatric Department - CHU Montpellier - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alain MAKINSON</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases - CHU Montpellier- France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence SLAMA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Infectious Diseases - Hôtel Dieu Hospital Paris- France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Maladies Infectieuses, CHU Hôtel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Frailty</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

